Therefore, it is worthwhile to investigate MondoA and carbohydrate response element-binding protein (ChREBP) nutrient-sensing factors as potential therapeutic targets for protection against obesity, T2DM, and metabolic diseases. Here, MLXIPL is linked to metabolic disease.